Wellington Management Group LLP Takes Position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Wellington Management Group LLP acquired a new position in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 65,633 shares of the biopharmaceutical company’s stock, valued at approximately $379,000.

A number of other hedge funds also recently bought and sold shares of INO. State Street Corp grew its stake in Inovio Pharmaceuticals by 11.7% in the third quarter. State Street Corp now owns 490,662 shares of the biopharmaceutical company’s stock valued at $2,836,000 after purchasing an additional 51,414 shares during the last quarter. Atom Investors LP bought a new stake in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $103,000. MetLife Investment Management LLC grew its position in shares of Inovio Pharmaceuticals by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 8,546 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 3,630 shares in the last quarter. Finally, FMR LLC lifted its position in Inovio Pharmaceuticals by 370.1% during the third quarter. FMR LLC now owns 27,261 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 21,462 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on INO shares. HC Wainwright reduced their price target on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Monday, November 18th. Royal Bank of Canada reduced their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. Finally, Oppenheimer decreased their price target on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $38.00.

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $1.84 on Friday. The business has a fifty day moving average of $4.53 and a 200 day moving average of $6.87. Inovio Pharmaceuticals, Inc. has a 1 year low of $1.74 and a 1 year high of $14.75. The firm has a market capitalization of $48.02 million, a price-to-earnings ratio of -0.53 and a beta of 0.75.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.